Private equity investor PGPE Limited reported an 8.6% decline in net asset value on a total-return basis for the first half of 2026, even as its shares rose 1.34% to $7.50 following the release of earnings figures.
The Amsterdam-listed firm distributed approximately EUR 111 million to shareholders during the period, equivalent to 14% of net assets, as it monetized holdings including Clario, Vishal Mega Mart and Galderma. Clario generated EUR 23 million for PGPE at an enterprise value exceeding $9 billion, realizing a multiple near 3x invested capital. Vishal Mega Mart contributed over EUR 15 million with a money multiple above 8.5x and a distributed-to-paid-in multiple near 5x, while Galderma’s full exit delivered a 3.5x multiple.
PGPE deployed EUR 13 million into new investments during the half and returned a total EUR 36 million to shareholders through a EUR 22 million interim dividend in June and EUR 13 million in share buybacks. Post-period buybacks totaled EUR 5 million, leaving EUR 51 million in cash and EUR 150 million available under an undrawn revolving credit facility.
Portfolio performance showed mixed trends. The top 20 holdings recorded 4.5% EBITDA growth over the prior 12 months, a deceleration from the firm’s historical 13%-15% annual range. Younger companies, representing just over 20% of NAV, delivered a blended internal rate of return near 20% with double-digit EBITDA growth. The top 10 holdings account for roughly 40% of NAV, while listed positions make up 9% of the portfolio.
Management noted that 80% of investments made before 2021 have been fully realized, achieving a 2.7x capital multiple, with remaining pre-2021 assets marked below 2x on a blended basis. The 2021-2023 vintages, comprising about half of NAV, remain in focus as the firm targets a return to historical growth rates by 2027.
PGPE’s cash position and credit capacity support near-term flexibility, with debt maturities for Emeria and Ammega due in 2028. The company plans to send a dual share class proposal circular and prospectus to shareholders in early September, while the Aroma-Zone transaction remains targeted for completion by year-end subject to regulatory approval.
